Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by xena555on Jul 24, 2019 10:49am

78 Views

Post# 29954481

RE:RE:BOOM

I hear you, but I would point out that AMRN has never had positve earnings- analysts predict that they will have their first +ve EPS quarter in Q1 of 2020.....and their market cap is $6.4 BLN (us$) vs ACST at $177mm currently.......which means AMRN is currently trading at 36 times the valuation of ACST.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity